Samsung Unifies Boston Imaging & NeuroLogica Under Samsung HME America, Announces Strategic Rebrand

The move consolidates the company’s ultrasound, digital radiography, and computed tomography (CT) operations into an integrated structure aligned with the global Samsung brand.

Samsung Medison announced that its U.S. medical imaging businesses, Boston Imaging and NeuroLogica, will now operate under a single corporate identity: Samsung HME (Healthcare and Medical Equipment) America.

The move consolidates the company’s ultrasound, digital radiography, and computed tomography (CT) operations into an integrated structure aligned with the global Samsung brand.

The rebrand reflects Samsung’s strategic focus on advancing medical imaging technology and expanding its presence in the U.S. healthcare market. The unified organization aims to enhance clinical collaboration, operational consistency, and product innovation across its portfolio.

“This milestone represents more than a name change,” said Kyu Tae Yoo, CEO of Samsung Medison and Division Head of Samsung HME at Samsung Electronics. “It reinforces Samsung’s long-term commitment to healthcare providers nationwide and reflects the growth and maturity of our U.S. medical imaging organization.”

Tracy Bury, Chief Commercial Officer, added that the new structure allows for greater customer engagement, streamlined operations, and faster innovation. “With a unified organization, we can deliver deeper collaboration and a more consistent experience across ultrasound, digital radiography, and CT,” she said.

Recent product advancements from Samsung HME America include the R20 and Z20 ultrasound systems, offering enhanced image quality and AI-powered decision-support tools. Samsung is also expanding its digital radiography portfolio with innovations targeting dose reduction and improved workflow, and its CT business continues to advance photon counting detector technology for point-of-care imaging.

The rebrand follows Samsung’s acquisition of Sonio, a French AI-driven prenatal ultrasound startup, which strengthens the company’s AI capabilities in early-stage fetal abnormality detection. The integration of AI across imaging platforms is central to Samsung HME America’s strategy to improve patient outcomes and support healthcare providers with precise clinical tools.

Samsung HME America will serve as the global headquarters and U.S. manufacturing hub for its CT business, emphasizing its role in developing next-generation imaging solutions. The company plans further AI releases, strategic partnerships, and product introductions throughout 2026.

Stay tuned for more such updates on Digital Health News